Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.…
Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
Aclarion (NASDAQ: ACON) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 1.222 USD on 20 November 2026, down 84.2% over 52 weeks. Its 52-week range is 1.220 USD to 9.360 USD, and it trades at the bottom of that range.
Its market capitalisation is 3.52M USD.
Aclarion reports return on equity of -56.4% and revenue up 78.1% year over year.
It holds more cash than debt, a net cash position of 14.20M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.